Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2017 / Masters of the Bench / Claus Michael Lehr

Claus-Michael Lehr

Head, Department of Drug Delivery, Helmholtz-Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research (HZI), Saarland University

  • Profile

Meet Claus-Michael Lehr

“I am passionate about the convergence of scientific challenges required to safely deliver drugs across biological barriers. Drug delivery is like a triathlon you must be good in more than one discipline – biology, chemistry, physics, medicine and engineering – to reach your goal. When we started our new Helmholtz Institute a few years back, I realized that there are many unexplored needs and opportunities for advanced drug delivery research in the context of infectious diseases.

“I would like to see drug delivery considered as a subject of strategic research rather than a mere development task of ‘formulating’ a given active molecule for (pre)clinical testing.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.